These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17102594)
1. Suppressive effect of modified dominant negative RAS mutant on human cancer by gene transfer with non-viral vector. Suzuki H; Kuzumaki S; Nakagawa K; Takimoto M; Shichinohe T Cancer Biol Ther; 2006 Nov; 5(11):1487-91. PubMed ID: 17102594 [TBL] [Abstract][Full Text] [Related]
2. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026 [TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. Watanabe T; Shinohara N; Sazawa A; Takimoto M; Hashimoto A; Koyanagi T; Kuzumaki N Int J Cancer; 2001 Jun; 92(5):712-7. PubMed ID: 11340577 [TBL] [Abstract][Full Text] [Related]
4. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Ogiso Y; Sakai N; Watari H; Yokoyama T; Kuzumaki N Gene Ther; 1994 Nov; 1(6):403-7. PubMed ID: 7584106 [TBL] [Abstract][Full Text] [Related]
5. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells. Watanabe T; Shinohara N; Sazawa A; Kobayashi Y; Ogiso Y; Kimura T; Takiguchi M; Yasuda J; Hashimoto A; Koyanagi T; Kuzumaki N Cancer Lett; 2000 Feb; 149(1-2):195-202. PubMed ID: 10737724 [TBL] [Abstract][Full Text] [Related]
6. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Senmaru N; Shichinohe T; Takeuchi M; Miyamoto M; Sazawa A; Ogiso Y; Takahashi T; Okushiba S; Takimoto M; Kato H; Kuzumaki N Int J Cancer; 1998 Oct; 78(3):366-71. PubMed ID: 9766573 [TBL] [Abstract][Full Text] [Related]
7. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823 [TBL] [Abstract][Full Text] [Related]
8. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y]. Yokoyama T Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597 [TBL] [Abstract][Full Text] [Related]
9. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation. Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Lee HY; Suh YA; Lee JI; Hassan KA; Mao L; Force T; Gilbert BE; Jacks T; Kurie JM Clin Cancer Res; 2002 Sep; 8(9):2970-5. PubMed ID: 12231543 [TBL] [Abstract][Full Text] [Related]
11. Development of HVJ envelope vector and its application to gene therapy. Kaneda Y; Yamamoto S; Nakajima T Adv Genet; 2005; 53():307-32. PubMed ID: 16240999 [TBL] [Abstract][Full Text] [Related]
12. The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines. Shinohara N; Ogiso Y; Tanaka M; Sazawa A; Harabayashi T; Koyanagi T J Urol; 1997 Sep; 158(3 Pt 1):908-11. PubMed ID: 9258117 [TBL] [Abstract][Full Text] [Related]
13. Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes. Tashiro H; Aoki M; Isobe M; Hashiya N; Makino H; Kaneda Y; Ogihara T; Morishita R J Mol Cell Cardiol; 2005 Sep; 39(3):503-9. PubMed ID: 16040050 [TBL] [Abstract][Full Text] [Related]
14. Viral-mediated gene transfer for cancer treatment. Wilson DR Curr Pharm Biotechnol; 2002 Jun; 3(2):151-64. PubMed ID: 12022258 [TBL] [Abstract][Full Text] [Related]
15. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Kaneda Y; Nakajima T; Nishikawa T; Yamamoto S; Ikegami H; Suzuki N; Nakamura H; Morishita R; Kotani H Mol Ther; 2002 Aug; 6(2):219-26. PubMed ID: 12161188 [TBL] [Abstract][Full Text] [Related]
16. Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. Chen LM; Le HY; Qin RY; Kumar M; Du ZY; Xia RJ; Deng J World J Gastroenterol; 2005 Feb; 11(6):831-8. PubMed ID: 15682475 [TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878 [TBL] [Abstract][Full Text] [Related]
18. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Zhang YA; Nemunaitis J; Tong AW Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Tu SP; Cui JT; Liston P; Huajiang X; Xu R; Lin MC; Zhu YB; Zou B; Ng SS; Jiang SH; Xia HH; Wong WM; Chan AO; Yuen MF; Lam SK; Kung HF; Wong BC Gastroenterology; 2005 Feb; 128(2):361-75. PubMed ID: 15685548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]